好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Edaravone Protects Human Brain Microvascular Cells Against Traumatic Brain Injury Induced Oxidative Stress
Cerebrovascular Disease and Interventional Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
5-017
The objective of this study is to characterize the effects of edaravone on human brain microvascular endothelial cells in the context of TBI induced oxidative stress and BBB disruption.  
Traumatic brain injury (TBI) is a leading cause of morbidity worldwide and a major risk factor for neurological disease. TBI triggers overproduction of reactive oxygen species (ROS) including hydrogen peroxide (H202), leading to mitochondrial damage in microvascular endothelial cells, the innermost monolayer of the blood-brain barrier (BBB), resulting in barrier disruption and increased risk for cerebral edema and intracranial hypertension. Edaravone is an FDA-approved free radical scavenger approved for delaying motor neuron degeneration in ALS and has been shown to protect the BBB in diabetic stroke models. The role of edaravone as a BBB protectant in the context of TBI is not yet known.  
Human brain microvascular endothelial cells (HBMECs) were seeded in transwell inserts, simulating a BBB monolayer. Cells were exposed to increasing concentrations of edaravone and challenged with H202, a known ROS generated in TBI. Microvascular permeability was measured using FITC-Dextran fluorescent tracer (10 kDa). Cell viability was measured using Calcein AM and ROS formation was measured using ROS detection assay.
Results indicate that H202 challenged cells resulted in hyperpermeability across the microvascular monolayer. When cells were pretreated with edaravone at 1, 5, and 10 μM for 24 hours, microvascular permeability was restored. Edaravone treatment reduced H202 induced ROS formation and, on its own, did not significantly affect cell viability. However, edaravone did restore viability in challenged cells.

The antioxidant edaravone is a promising neurovascular protectant that may mitigate TBI induced ROS and BBB hyperpermeability. These data point to a role for edaravone as a TBI therapeutic, with implications for its use as a BBB protectant against oxidative stress.  

Authors/Disclosures
Gabi S. Seplovich
PRESENTER
Miss Seplovich has nothing to disclose.
Binu Tharakan, PhD Dr. Tharakan has nothing to disclose.
Firas Kobeissy (Morehouse School of Medicine) No disclosure on file
Mojtaba Golpich, PhD Dr. Golpich has nothing to disclose.
Yehia Mechref, PhD The institution of Prof. Mechref has received research support from NIH. Prof. Mechref has received intellectual property interests from a discovery or technology relating to health care.